-
公开(公告)号：US20220152069A1
公开(公告)日：2022-05-19
申请号：US17590771
申请日：2022-02-01
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/7032 , A61P31/14 , A61K9/00 , A61K45/06
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11779561B2
公开(公告)日：2023-10-10
申请号：US17590771
申请日：2022-02-01
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/351 , A61K31/235 , A61K9/00 , A61K31/513 , A61K31/427 , A61K31/4709 , A61K31/472 , A61K31/4433 , A61K31/685 , A61K38/21 , A61K31/46 , A61K38/16 , A61K39/395 , A61K31/675 , A61K31/395 , A61K31/353 , A61K31/499 , A61K31/16 , A61K31/426 , A61K31/4045 , A61K31/343 , A61K31/13 , A61K31/4245 , A61K31/7072 , A61K31/708 , A61K31/506 , A61K31/52 , A61K31/551 , A61K31/4985 , A61K31/553 , A23L33/00 , A23L33/10 , A61P31/14 , A61K31/7032 , A61K45/06
CPC classification number: A61K31/351 , A23L33/10 , A23L33/40 , A61K9/008 , A61K9/0056 , A61K9/0078 , A61K31/13 , A61K31/16 , A61K31/235 , A61K31/343 , A61K31/353 , A61K31/395 , A61K31/4045 , A61K31/426 , A61K31/427 , A61K31/4245 , A61K31/4433 , A61K31/46 , A61K31/472 , A61K31/4709 , A61K31/499 , A61K31/4985 , A61K31/506 , A61K31/513 , A61K31/52 , A61K31/551 , A61K31/553 , A61K31/675 , A61K31/685 , A61K31/708 , A61K31/7032 , A61K31/7072 , A61K38/16 , A61K38/21 , A61K38/212 , A61K38/217 , A61K39/3955 , A61K45/06 , A61P31/14 , A23V2002/00
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I):
or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20220218730A1
公开(公告)日：2022-07-14
申请号：US17699784
申请日：2022-03-21
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/7048 , A61P25/18 , C07D317/68 , C07C69/90 , C07D207/34 , C07D231/14 , C07H15/22 , C07H15/26 , A61K31/36 , A61K31/235 , A61K31/40 , A61K31/415 , A61K31/7034 , A23L33/10 , A23L33/00
Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC═OR6, (C═O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).
-
公开(公告)号：US11382924B2
公开(公告)日：2022-07-12
申请号：US17377829
申请日：2021-07-16
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/7032 , A61K9/00 , A61P31/14 , A61K45/06
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
公开(公告)号：US20220054516A1
公开(公告)日：2022-02-24
申请号：US17377829
申请日：2021-07-16
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/7032 , A61K45/06 , A61P31/14 , A61K9/00
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240180945A1
公开(公告)日：2024-06-06
申请号：US18493421
申请日：2023-10-24
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/7048 , A23L33/00 , A23L33/10 , A61K31/235 , A61K31/36 , A61K31/40 , A61K31/415 , A61K31/7034 , A61P25/18 , C07C69/90 , C07D207/34 , C07D231/14 , C07D317/68 , C07H15/22 , C07H15/26
CPC classification number: A61K31/7048 , A23L33/10 , A23L33/40 , A61K31/235 , A61K31/36 , A61K31/40 , A61K31/415 , A61K31/7034 , A61P25/18 , C07C69/90 , C07D207/34 , C07D231/14 , C07D317/68 , C07H15/22 , C07H15/26 , A23V2002/00
Abstract: A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC═OR6, (C═O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).-
公开(公告)号：US20210251945A1
公开(公告)日：2021-08-19
申请号：US17014774
申请日：2020-09-08
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/351 , A61P31/14 , A61K31/235 , A61K9/00 , A61K31/513 , A61K31/427 , A61K31/4709 , A61K31/472 , A61K31/4433 , A61K31/685 , A61K38/21 , A61K31/46 , A61K38/16 , A61K39/395 , A61K31/675 , A61K31/395 , A61K31/353 , A61K31/499 , A61K31/16 , A61K31/426 , A61K31/4045 , A61K31/343 , A61K31/13 , A61K31/4245 , A61K31/7072 , A61K31/708 , A61K31/506 , A61K31/52 , A61K31/551 , A61K31/4985 , A61K31/553 , A23L33/00 , A23L33/10
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11793823B2
公开(公告)日：2023-10-24
申请号：US17699784
申请日：2022-03-21
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: C07D207/34 , A61K31/7048 , A23L33/10 , A23L33/00 , A61P25/18 , A61K31/235 , A61K31/36 , A61K31/40 , A61K31/415 , A61K31/7034 , C07C69/90 , C07D231/14 , C07D317/68 , C07H15/22 , C07H15/26
CPC classification number: A61K31/7048 , A23L33/10 , A23L33/40 , A61K31/235 , A61K31/36 , A61K31/40 , A61K31/415 , A61K31/7034 , A61P25/18 , C07C69/90 , C07D207/34 , C07D231/14 , C07D317/68 , C07H15/22 , C07H15/26 , A23V2002/00
Abstract: A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently are halogen, OH, OR5, CH2OR5, CO2H, OC═OR6, (C═O)R6, R6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).-
公开(公告)号：US11154531B2
公开(公告)日：2021-10-26
申请号：US17014774
申请日：2020-09-08
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Yi-Wen Mao , Lu-Ping Lu , Wei-Hua Chang , Han-Yi Hsieh , Jhe Wei Hu , Tsai-Miao Shih , ChanHui Huang
IPC: A61K31/351 , A61P31/14 , A61K31/7024 , A61K36/82 , A61K36/22 , A61K36/49 , A23L33/105 , A61K31/235 , A61K9/00 , A61K31/513 , A61K31/427 , A61K31/4709 , A61K31/472 , A61K31/4433 , A61K31/685 , A61K38/21 , A61K31/46 , A61K38/16 , A61K39/395 , A61K31/675 , A61K31/395 , A61K31/353 , A61K31/499 , A61K31/16 , A61K31/426 , A61K31/4045 , A61K31/343 , A61K31/13 , A61K31/4245 , A61K31/7072 , A61K31/708 , A61K31/506 , A61K31/52 , A61K31/551 , A61K31/4985 , A61K31/553 , A23L33/00 , A23L33/10
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.016 seconds)
